Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5-fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC).Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points.Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7\% (95\% confidence interval=7.7-25.7\%). After a median follow-up of 73.5 months, 23 patients (34.8\%) had experienced relapse. Five-year actuarial RFS and OS rates were 64\% and 73\%, respectively. Five-year actuarial RFS was 91.7\% in the ypCR group versus 57.8\% in non-ypCR cases.Long-term local control and survival after this very well-tolerated regimen appear encouraging.
|Data di pubblicazione:||2013|
|Titolo:||Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer.|
|Autore/i:||E. Fontana; F. Pucci; R. Camisa; S. Bui; S. Galdy; F. Leonardi; F. V. Negri; E. Anselmi; P. L. Losardo; L. Roncoroni; P. Dell'abate; P. Crafa; S. Cascinu; A. Ardizzoni|
|Codice identificativo ISI:||WOS:000315424000052|
|Codice identificativo Scopus:||2-s2.0-84875900868|
|Codice identificativo Pubmed:||23393374|
|Citazione:||Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. / E. Fontana; F. Pucci; R. Camisa; S. Bui; S. Galdy; F. Leonardi; F. V. Negri; E. Anselmi; P. L. Losardo; L. Roncoroni; P. Dell'abate; P. Crafa; S. Cascinu; A. Ardizzoni. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 33:Feb;33(2)(2013), pp. 725-730.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris